Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf149 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Matthias Harlass und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Early Detection of Cancer, Feces, Hemoglobins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Laboratory Computing Resource Center at Argonne National Laboratory, National Energy Research Scientific Computing Center, NCI NIH HHS.
Abstract (Originalsprache)
Background
Fecal immunochemical test (FIT) performance for colorectal cancer screening varies by age and sex, yet most FIT-based screening programs use uniform positivity thresholds. This study assessed the potential benefits of stratifying FIT thresholds based on age and sex.
Methods
We conducted a meta-analysis of FIT sensitivity and specificity at various positivity thresholds by age and sex. We then used these estimates in 2 microsimulation models of colorectal cancer and projected lifetime clinical outcomes, incremental costs, and quality-adjusted life-years (QALYs) gained from age- and sex-stratified FIT strategies. FIT thresholds ranged from 10 to 50 µg hemoglobin per gram of feces.
Results
For current uniform FIT screening (20 µg hemoglobin/gram of feces), models projected 85.67 to 122.15 QALYs gained at incremental costs of ‒$982 to $504 per 1000 individuals compared with no screening. At equivalent costs to current uniform screening, only 1 model found stratified FIT approaches cost-effective, yielding a marginal increase of 1.04 and 1.10 QALYs gained/1000 female and male individuals, respectively. At a willingness-to-pay threshold of $100 000/QALYs gained, both models found stratified FIT cutoffs to be the best strategy, with cutoffs being equal to or higher for males and lowest at older ages (70-75 years). Uniform strategies showed comparable effectiveness, falling within 1 quality-adjusted life-day per person of efficient strategies at up to $112 more per person. Results were sensitive to FIT test performance characteristics and 1-time setup costs.
Conclusion
Stratifying FIT thresholds by age and sex may be cost-effective compared to current screening. The gain in expected health benefits with stratified FIT screening, however, is likely small.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, United States.
- Department of Radiology, Harvard Medical School, Boston, MA, United States.
- Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, United States.
- Biostatistics Program, Public Health Sciences Division, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, WA, United States.
- Engineering and Applied Sciences Department, RAND Corporation, Arlington VA, United States.
ORCID-Profile: Matthias Harlass, Amy B Knudsen, Daan Nieboer, Luuk A van Duuren, Karen M Kuntz, Carolyn M Rutter, Pedro Nascimento de Lima, Nicholson Collier, Jonathan Ozik, Anne I Hahn, Fernando Alarid-Escudero, Ann G Zauber, John M Inadomi, Reinier G S Meester, Iris Lansdorp-Vogelaar
Förderung
- Laboratory Computing Resource Center at Argonne National Laboratory
- National Energy Research Scientific Computing Center
- NCI NIH HHS
- Department of Energy Office of Science User Facility
- NIH HHS
- Cancer Intervention and Surveillance Modelling Network
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Harlass, M., Knudsen, A. B., Nieboer, D., van Duuren, L. A., Kuntz, K. M., Rutter, C. M., Nascimento de Lima, P., Collier, N., Ozik, J., Hahn, A. I., Alarid-Escudero, F., Zauber, A. G., Inadomi, J. M., Meester, R. G. S., & Lansdorp-Vogelaar, I. (2025). Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf149
Vancouver
Harlass M, Knudsen AB, Nieboer D, van Duuren LA, Kuntz KM, Rutter CM, et al. Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf149
BibTeX
@article{Harlass2025,
author = {Harlass, Matthias and Knudsen, Amy B and Nieboer, Daan and van Duuren, Luuk A and Kuntz, Karen M and Rutter, Carolyn M and Nascimento de Lima, Pedro and Collier, Nicholson and Ozik, Jonathan and Hahn, Anne I and Alarid-Escudero, Fernando and Zauber, Ann G and Inadomi, John M and Meester, Reinier G S and Lansdorp-Vogelaar, Iris},
title = {Benefits of colorectal cancer screening using fecal immunochemical testing with varying positivity thresholds by age and sex},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf149}
}
EUVIMED